China Eastern Orders 25 Airbus A330neo Jets in $9.35 Billion Deal to Boost International Expansion 
Johns Hopkins University Lays Off 110 Employees as Federal Research Funding Declines 
US Judge Seeks Explanation for DOJ’s Decision to Drop Gautam Adani Bribery Case 
Samsung, SK Hynix to Unveil Record AI and Semiconductor Investment Plans Worth Over $646 Billion 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
SpaceX, Charter Communications Explore Mobile Partnership to Expand Starlink Wireless Service 
Nomura Stock Upgraded to Buy by BofA as Stronger ROE and Earnings Growth Boost Outlook 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
Bayer Wins Major U.S. Supreme Court Roundup Lawsuit, Shares Surge 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Bristol Myers Squibb acquired RayzeBio for a staggering amount of $4.1 billion. The global biopharmaceutical company is investing to bolster its cancer therapy portfolio and business.
Terms of the Agreement
This Bristol Myers Squibb deal is the latest one that it has signed in less than a week. It has just announced its purchase of Karuna Therapeutics, a drug developer, on Friday, as per Reuters.
With the buyout deal, Bristol Myers will have access to RayzeBio's drug production facility located in Indianapolis, Indiana. It was agreed that the former would pay $62.50 in cash for every share of RayzeBio.
Looking Forward to Growth as Bristol Myers and RayzeBio Merge
Bristol Myers Squibb's acquisition of RayzeBio is a strategic move that aligns with the recent gush of mergers and acquisition agreements in the pharmaceutical industry. The companies' respective management teams believe this deal will fuel growth within the second half of this decade.
"This transaction enhances our increasingly diversified oncology portfolio by bringing a differentiated platform and pipeline, and further strengthens our growth opportunities in the back half of the decade and beyond," Bristol Myers Squibb's chief executive officer, Christopher Boerner, Ph.D., said in a press release. "We look forward to supporting and accelerating RayzeBio's preclinical and clinical programs and advancing its highly innovative radiopharmaceutical platform."
RayzeBio's president and CEO, Ken Song, M.D., further stated, "Despite therapeutic advances in recent years, the need for more effective treatments in solid tumors persists, and radiopharmaceutical therapeutics are positioned to be an important next wave of innovation in oncology therapy."
The biotech firm's chief added, "Bristol Myers Squibb's well-established presence in oncology and deep expertise in developing, commercializing, and manufacturing treatments on a global scale makes it the ideal partner for RayzeBio at this important moment in our evolution and I am very excited to see what our team clinches as part of Bristol Myers Squibb."
Photo by: Bristol Myers Squibb Media Gallery
